BOLT Bolt Biotherapeutics Inc

InvestorPlace - Stock Market News, Stock Advice & Trading Tips BOLT stock results show that Bolt Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth...

BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones BDC-3042 Phase 1 study successfully cleared safety assessments in the first...

REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer...